Market Place
Sourcing Support
Galderma Receives FDA Approval for Nemluvio For Atopic Dermatitis
14 Dec 2024 //
BUSSINESSWIRE
CHMP Recommends Galderma’s Nemolizumab For Atopic Dermatitis
13 Dec 2024 //
BUSINESSWIRE
Galderma Bets on Skin Drug to Turn Around Pharma Business
29 Nov 2024 //
WSJ
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology
28 Nov 2024 //
BUSINESSWIRE
Galderma Celebrates 25 Years of Sculptra® with New China Approval
04 Nov 2024 //
BUSINESSWIRE
Galderma Hosts 650 Healthcare Pros For Aesthetic Trends Event
25 Oct 2024 //
BUSINESSWIRE
Galderma Reports $3.259B Net Sales in First Nine Months of 2024
24 Oct 2024 //
BUSINESSWIRE
Galderma Reports Record Net Sales Of $3.259B In 2024
24 Oct 2024 //
BUSINESSWIRE
ASDS 2024: Phase III READY-4 Data Shows Safety Of Relfydess™
21 Oct 2024 //
BUSINESSWIRE
Galderma To Share Nemolizumab Data At EADV 2024 Sessions
25 Sep 2024 //
BUSINESSWIRE
Galderma Reaffirms Leadership In Dermatology With Presence At EADV 2024
17 Sep 2024 //
BUSINESSWIRE
Galderma Shows Leadership At EADV 2024
16 Sep 2024 //
BUSINESSWIRE
Amber Specialty Pharmacy To Distribute Galderma`s Prurigo Nodularis Med
12 Sep 2024 //
BUSINESSWIRE
Galderma Successfully Issued an Inaugural CHF 500 Million Bond
29 Aug 2024 //
BUSINESSWIRE
FDA Approves Galderma`s Nemluvio For Adult Prurigo Nodularis
14 Aug 2024 //
BUSINESSWIRE
Galderma To Partner With L`Oréal In Dermatology Research
05 Aug 2024 //
BUSINESSWIRE
Galderma`s Relfydess™ Approved For Use In Europe
30 Jul 2024 //
BUSINESSWIRE
Galderma`s Nemolizumab Shows Positive Results In Atopic Dermatitis
24 Jul 2024 //
BUSINESSWIRE
Galderma Reports 2.2B USD H1 2024 Sales, 10.8% YoY Growth
24 Jul 2024 //
BUSINESSWIRE
Galderma Granted Manufacturing License Updates for New Biologics Capabilities
23 Jul 2024 //
CONTRACT PHARMA
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
09 Jul 2024 //
BUSINESSWIRE
Galderma Granted Key Manufacturing License Updates
19 Jun 2024 //
BUSINESSWIRE
Galderma Restylane® Volyme™ Launch: Fast-Growing China Aesthetics Market
23 May 2024 //
BUSINESSWIRE
Galderma Filings For Nemolizumab In 4 More Countries
07 May 2024 //
BUSINESSWIRE
Galderma Q1 Sales Top $1B, Up 12.4% YoY
24 Apr 2024 //
BUSINESSWIRE
Galderma Announces Full Exercise of Over-Allotment Option
26 Mar 2024 //
BUSINESSWIRE
Galderma Prices IPO at CHF 53 Per Share and Will Start Trading
20 Mar 2024 //
BUSINESSWIRE
AMWC 2024: Galderma to Share New Data From Injectable Aesthetic Portfolio
19 Mar 2024 //
BUSINESSWIRE
Galderma kicks off the process for $2.6B IPO
13 Mar 2024 //
FIERCE PHARMA
Galderma Announces Intention to Float on the SIX Swiss Exchange
06 Mar 2024 //
BUSINESSWIRE
Galderma Announces Record 2023 Net Sales of Over 4 B USD
29 Feb 2024 //
BUSINESSWIRE
Galderma`s net sales top $4 billion in 2023 ahead of potential IPO
28 Feb 2024 //
REUTERS
Galderma to Showcase Updates From Broad, Innovative and Dermatology Portfolio
27 Feb 2024 //
BUSINESSWIRE
CORRECTING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab
14 Feb 2024 //
BUSINESSWIRE
Galderma Announces Regulatory Filing Acceptance for Nemolizumab
13 Feb 2024 //
BUSINESSWIRE
Galderma Launches ‘NEXT’, Trend Report That Unveils the Future of Aesthetics
07 Feb 2024 //
BUSINESSWIRE
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report
06 Feb 2024 //
BUSINESSWIRE
Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio
25 Jan 2024 //
BUSINESSWIRE
Galderma Announces Regulatory Approval for Restylane® SHAYPE™
22 Jan 2024 //
BUSINESSWIRE
Results From Galderma’s PIIIb Trials Demonstrate Effect of RelabotulinumtoxinA
30 Nov 2023 //
BUSINESSWIRE
Galderma Reports Net Sales of 3 B USD for First Nine Months of 2023
21 Nov 2023 //
BUSINESSWIRE
PatientFi and Galderma Partner to Offer Memberships for Aesthetic Treatments
09 Nov 2023 //
BUSINESSWIRE
Galderma Phase III Data Published in the New England Journal of Medicine
26 Oct 2023 //
BUSINESSWIRE
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
13 Oct 2023 //
BUSINESSWIRE
Phase III Trials Demonstrate Nemolizumab’s Efficacy in Atopic Dermatitis
11 Oct 2023 //
BUSINESSWIRE
Galderma renews annual breast cancer awareness campaign
06 Oct 2023 //
ENDPTS
Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
04 Oct 2023 //
BUSINESSWIRE
Galderma`s liquid botulinum toxin bid nixed by FDA
03 Oct 2023 //
FIERCE PHARMA
Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023
27 Jul 2023 //
BUSINESSWIRE
Ipsen ends neurotoxin pact with Galderma after arbitration cases
27 Jul 2023 //
ENDPTS
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment
28 Jun 2023 //
BUSINESSWIRE
Galderma raises $1 bill through private placement ahead of potential IPO
27 Jun 2023 //
FIERCE PHARMA
Galderma Raises USD 1B for Newly Issued Shares in a Private Placement Round
26 Jun 2023 //
BUSINESSWIRE
PIII Results Demonstrate nemolizumab’s Impact on Prurigo Nodularis
18 Mar 2023 //
BUSINESSWIRE
Galderma Delivers Strong FY 2022 Growth Driven by Commercial Performance
13 Mar 2023 //
BUSINESSWIRE
BridgeBio company sells off rare disease candidate to Galderma partner
28 Jan 2023 //
ENDPTS
Galderma to Share Latest Data Demonstrating High Aesthetic Improvement
20 Jan 2023 //
BUSINESSWIRE
Galderma exploring a 5th manufacturing facility to meet demand
13 Oct 2022 //
FIERCEPHARMA
